- Home
- IOR vs BOLD Comparison
IOR vs BOLD Comparison
Compare IOR & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOR
- BOLD
- Stock Information
- Founded
- IOR 1984
- BOLD 2018
- Country
- IOR United States
- BOLD United States
- Employees
- IOR N/A
- BOLD N/A
- Industry
- IOR Real Estate Investment Trusts
- BOLD
- Sector
- IOR Real Estate
- BOLD
- Exchange
- IOR Nasdaq
- BOLD Nasdaq
- Market Cap
- IOR 68.6M
- BOLD 81.0M
- IPO Year
- IOR N/A
- BOLD 2024
- Fundamental
- Price
- IOR $16.87
- BOLD $3.24
- Analyst Decision
- IOR
- BOLD Strong Buy
- Analyst Count
- IOR 0
- BOLD 3
- Target Price
- IOR N/A
- BOLD $23.00
- AVG Volume (30 Days)
- IOR 1.2K
- BOLD 60.3K
- Earning Date
- IOR 11-07-2024
- BOLD 11-07-2024
- Dividend Yield
- IOR N/A
- BOLD N/A
- EPS Growth
- IOR 5.45
- BOLD N/A
- EPS
- IOR 1.47
- BOLD N/A
- Revenue
- IOR N/A
- BOLD N/A
- Revenue This Year
- IOR N/A
- BOLD N/A
- Revenue Next Year
- IOR N/A
- BOLD N/A
- P/E Ratio
- IOR $11.42
- BOLD N/A
- Revenue Growth
- IOR N/A
- BOLD N/A
- 52 Week Low
- IOR $11.66
- BOLD $2.82
- 52 Week High
- IOR $19.00
- BOLD $15.24
- Technical
- Relative Strength Index (RSI)
- IOR 46.07
- BOLD N/A
- Support Level
- IOR $16.50
- BOLD N/A
- Resistance Level
- IOR $17.14
- BOLD N/A
- Average True Range (ATR)
- IOR 0.13
- BOLD 0.00
- MACD
- IOR 0.01
- BOLD 0.00
- Stochastic Oscillator
- IOR 35.21
- BOLD 0.00
About IOR Income Opportunity Realty Investors Inc.
Income Opportunity Realty Investors Inc is a U.S.-based company that is an externally managed company that invests in mortgage notes receivables and real property. Its business is managed by Pillar Income Asset Management, Inc. Pillar's duties include, but are not limited to, locating, evaluating and recommending real estate and real estate-related investment opportunities. Pillar also arranges its debt and equity financing with unaffiliated independent third party lenders and investors.
About BOLD Boundless Bio Inc. Common Stock
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.